Dizlin Pharmaceuticals has obtained a “Decision to Grant” by the European Patent Office for Infudopa SubC™, a new potential treatment for Parkinson’s disease

Dizlin Pharmaceuticals announced today that the European Patent Office (EPO) has issued a Decision to Grant a European patent pursuant to Article 97(1) EPC following examination of European patent application No. 18730319.3. The mention of the Grant was published in the European Patent Bulletin 21/04 on the 27th of January 2021. The Decision to Grant refers to Infudopa SubC™, a new potential treatment for reducing motor complications of Parkinson’s disease via continuous subcutaneous infusion.

A granted patent by EPO will protect the company’s innovative product Infudopa SubC™ for treatment of Parkinson’s disease in all markets in Europe, which have agreed to the Patent Cooperation Treaty (PCT) agreement.

”Strong patents are a prerequisite for successfully commercializing Dizlin Pharmaceutical’s scientific advances. I am therefore pleased to announce that the European Patent Office has decided to issue a Decision to Grant for the company’s innovative product Infudopa SubC™ for the treatment of Parkinson’s disease. This is an important milestone, not only pursuing the company’s patent strategy, but also in our aim to improve the lives of the Parkinson patients,” says Björn Velin, CEO of Dizlin Pharmaceuticals.

Leave a Reply